|

Gemcitabine (GEM) Clinical Trials

4 actively recruiting trials across 2 locations

▲ +2 trials since June 2026

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

  • Sun Yat-sen University1
  • Revolution Medicines, Inc.1
  • M.D. Anderson Cancer Center1
  • First Affiliated Hospital of Guangxi Medical University1

Indications

  • Cancer4
  • Refractory Germ1
  • Pediatric Relapsed1
  • Melphalan1
  • Prospective Observational Study1

Other2 trials

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
Phase 3
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
Phase 2

Tampa, Florida1 trial

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Moffitt Cancer Center

Phase 3

Houston, Texas1 trial

Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

MD Anderson Cancer Center

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.